Lp(a): from CV risk marker to therapeutic target

Meeting report with presentation slides, videos and online CME of a PACE-CME symposium held during ESC 2021, The Digital Experience.

Episodes 1-3 of 3

  • Lpa as therapeutic target  now and in the futureLpa as therapeutic target  now and in the future
    Lp(a): from CV risk marker to therapeutic target
    Lp(a) as therapeutic target - now and in the future
    • Prof. Erik Stroes, MD
      Prof. Erik Stroes, MD

      Prof. Erik Stroes, MD

  • Understanding the increased CV risk of high Lpa levelsUnderstanding the increased CV risk of high Lpa levels
    Lp(a): from CV risk marker to therapeutic target
    Understanding the increased CV risk of high Lp(a) levels
    • Prof. Florian Kronenberg, MD
      Prof. Florian Kronenberg, MD

      Prof. Florian Kronenberg, MD

  • Why focus on Lpa Why focus on Lpa
    Lp(a): from CV risk marker to therapeutic target
    Why focus on Lp(a)?
    • Prof. Naveed Sattar
      Prof. Naveed Sattar

      Prof. Naveed Sattar

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free